Unknown

Dataset Information

0

Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.

ABSTRACT:

SUBMITTER: Yoshida S 

PROVIDER: S-EPMC5457839 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Efficacy of an anti-CD22 antibody-monomethyl auristatin E conjugate in a preclinical xenograft model of precursor B-cell acute lymphoblastic leukemia.

Yoshida Sakiko S   Tuscano Emily E   Duong Connie C   Chung Jong J   Li Yueju Y   Beckett Laurel L   Tuscano Joseph M JM   Satake Noriko N  

Leukemia & lymphoma 20161005 5

Similar Datasets

Unknown Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate.
| S-EPMC5082301 | biostudies-literature
Unknown Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
| S-EPMC6063246 | biostudies-literature
Unknown Annexin A1-Targeted d-Peptide-Monomethyl Auristatin E Conjugate Enhanced Antitumor Effect of Monomethyl Auristatin E for Chemotherapy of Prostate Cancer.
| S-EPMC12329190 | biostudies-literature
Unknown Optimization of Adcitmer, a Monomethyl-Auristatin E bearing antibody-drug conjugate for the treatment of CD56-expressing cancers.
| S-EPMC11907074 | biostudies-literature
Unknown Preclinical evaluation of a novel antibody-drug conjugate targeting DR5 for lymphoblastic leukemia therapy.
| S-EPMC8173093 | biostudies-literature
Unknown Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.
| S-EPMC6588422 | biostudies-literature
Unknown Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy.
| S-EPMC9256669 | biostudies-literature
Unknown The CD123 antibody-drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia.
| S-EPMC11739898 | biostudies-literature
Unknown Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia.
| S-EPMC7501879 | biostudies-literature
Unknown Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
| S-EPMC6085421 | biostudies-literature